Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing
and trading of medicines[1]
- Market Cap ₹ 68.5 Cr.
- Current Price ₹ 40.0
- High / Low ₹ 107 / 33.3
- Stock P/E 6.52
- Book Value ₹ 36.3
- Dividend Yield 0.00 %
- ROCE 27.1 %
- ROE 26.3 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.10 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.6%
Cons
- Company has high debtors of 188 days.
- Working capital days have increased from 55.6 days to 112 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 92 | 114 | 131 | |
| 85 | 104 | 114 | |
| Operating Profit | 7 | 9 | 17 |
| OPM % | 8% | 8% | 13% |
| 1 | 1 | 1 | |
| Interest | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 4 | 7 | 13 |
| Tax % | 29% | 27% | 28% |
| 3 | 5 | 10 | |
| EPS in Rs | 5.59 | ||
| Dividend Payout % | 0% | 0% | 9% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 115% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -57% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| Last Year: | 26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 17 |
| Reserves | 12 | 17 | 45 |
| 19 | 26 | 25 | |
| 38 | 54 | 48 | |
| Total Liabilities | 69 | 98 | 135 |
| 10 | 12 | 11 | |
| CWIP | 3 | 0 | 4 |
| Investments | 0 | 0 | 0 |
| 55 | 86 | 120 | |
| Total Assets | 69 | 98 | 135 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| 5 | -5 | -13 | |
| -5 | -0 | 26 | |
| 1 | 5 | -4 | |
| Net Cash Flow | 1 | -0 | 9 |
| Free Cash Flow | -0 | -10 | -18 |
| CFO/OP | 93% | -32% | -53% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 128 | 159 | 188 |
| Inventory Days | 96 | 192 | 249 |
| Days Payable | 274 | 413 | 412 |
| Cash Conversion Cycle | -50 | -62 | 25 |
| Working Capital Days | 16 | 39 | 112 |
| ROCE % | 24% | 27% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Domestic Presence (States) Number of States ・Standalone data |
|
|
| International Markets Presence Number of Countries ・Standalone data |
||
| Number of Molecules Count ・Standalone data |
||
| Number of Permanent Employees Count ・Standalone data |
||
| Number of SKUs Count ・Standalone data |
||
| Revenue Share - Capsules/Others % ・Standalone data |
||
| Revenue Share - Liquid Externals % ・Standalone data |
||
| Revenue Share - Ointments/Creams % ・Standalone data |
||
| Revenue Share - Oral Powders (ORS) % ・Standalone data |
||
| Revenue Share from Madhya Pradesh % ・Standalone data |
||
| Outstanding Order Book Rs Crore ・Standalone data |
||
Documents
Announcements
-
General Updates
2 April 2026 - Zenith Drugs wins Karnataka government tender for 39,91,561 levocetirizine syrup bottles worth about Rs. 2.90 crore.
-
Trading Window
30 March 2026 - Trading window closed Apr 01, 2026 until 48 hours after audited results for FY/H1 ending Mar 31, 2026.
-
General Updates
10 February 2026 - GMP Certificate under Revised Schedule ‘M’ issued after 02 Feb 2026 inspection; valid till 12 Sep 2028.
-
General Updates
6 February 2026 - Awarded tender by MPPHCL to supply Itraconazole capsules; order value ₹87.98 Lacs (06-Feb-2026).
-
Reply to Clarification- Financial results
5 February 2026 - Clarifies IPO proceeds Rs.3,595.55 lakhs fully utilized by Sep 30, 2024; revised deviation filed Nov 14, 2024.
Business Overview:[1][2]
ZDL is a manufacturer of a range of healthcare drugs and allied products
which includes pharmaceutical formulations. It also caters to a diverse range of customers and generates revenue through various avenues, such as marketing of branded generic drugs, third-party job work manufacturing, government and institutional business, and exports through merchant dealers.